Cellular and Molecular Biomarkers in Patients With Lichen Planus
Lichen planus (LP) is a chronic inflammatory disease of unknown aetiology, affecting the skin and mucous membranes, characterised by a CD8+ cytotoxic T-cell infiltrate, associated with epithelial cell death and disruption of the basement membrane zone. In previous work, T cell antigen receptor (TCR) repertoire studies
| Condition(s) | Lichen Planus |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Lichen planus (LP) is a chronic inflammatory disease of unknown aetiology, affecting the skin and mucous membranes, characterised by a CD8+ cytotoxic T-cell infiltrate, associated with epithelial cell death and disruption of the basement membrane zone. In previous work, T cell antigen receptor (TCR) repertoire studies were performed. In all patients tested, whether with erosive or non-erosive LP, unique nucleotide sequences, called clonotypes, have been identified. They appear during the process of TCR gene rearrangement. These clonotypes are specific for human papillomavirus (HPV) in blood and lesions, suggesting antigenic stimulation of these clonotypes by a viral epitope of HPV, which crosses with an epitope on keratinocytes. The diagnosis of LP is made on the basis of clinical and hist |
| Who can participate | Inclusion Criteria: * Subject coming at the time of diagnosis of the disease before any systemic treatment, or at the time of a progressive episode of the disease, without systemic treatment or after cessation of immunomodulatory or immunosuppressive treatment * Ability to give their consent in writing * Must understand spoken and written French * Affiliated to the French social security or assimilated regimes Exclusion Criteria: * Dermatosis exclusively localised in the skin folds or on the face (risk of scarring from biopsies) |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Institut Pasteur |
| Locations | Besançon, France; Bobigny, France; Paris, France; Paris, France; Reims, France; Rouen, France |
| Start date | 2023-11-01 |
| NCT ID | NCT06451744 |
| Official listing | https://clinicaltrials.gov/study/NCT06451744 |